Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection

Journal of Molecular Diagnostics

Volumn 19, Issue 5, 2017, Pages 722-732

  Bartels, Stephan ^a   Persing, Sascha ^a   Hasemeier, Britta ^a   Schipper, Elisa ^a   Kreipe, Hans ^a   Lehmann, Ulrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING CELL FREE DNA; DNA; UNCLASSIFIED DRUG; CIRCULATING TUMOR DNA; TUMOR MARKER;

CONFERENCE PAPER; CONTROLLED STUDY; DNA DETERMINATION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LABORATORY TEST; LIMIT OF DETECTION; LUNG CANCER; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; DIAGNOSTIC TEST; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MALE; MOLECULAR DIAGNOSIS; MUTATION; NON SMALL CELL LUNG CANCER; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; STANDARDS;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; DIAGNOSTIC TESTS, ROUTINE; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 85027700411     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2017.05.008     Document Type: Article

References (26)

1. Oxnard, G.R., Thress, K.S., Alden, R.S., Lawrance, R., Paweletz, C.P., Cantarini, M., Yang, J.C., Barrett, J.C., Jänne, P.A., Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34 (2016), 3375–3382.
2. Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Bergethon, K., Shaw, A.T., Gettinger, S., Cosper, A.K., Akhavanfard, S., Heist, R.S., Temel, J., Christensen, J.G., Wain, J.C., Lynch, T.J., Vernovsky, K., Mark, E.J., Lanuti, M., Iafrate, A.J., Mino-Kenudson, M., Engelman, J.A., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 2011, 75ra26.
3. Thress, K.S., Brant, R., Carr, T.H., Dearden, S., Jenkins, S., Brown, H., Hammett, T., Cantarini, M., Barrett, J.C., EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90 (2015), 509–515.
4. Imamura, F., Uchida, J., Kukita, Y., Kumagai, T., Nishino, K., Inoue, T., Kimura, M., Oba, S., Kato, K., Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer 94 (2016), 68–73.
5. Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S.E., Cantarini, M., Barrett, J.C., Jänee, P.A., Oxnard, G.R., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21 (2015), 560–562.
6. Reck, M., Hermes, A., Tan, E.-H., Felip, E., Klughammer, B., Baselga, J., Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer 74 (2011), 1–6.
7. Overman, M.J., Modak, J., Kopetz, S., Murthy, R., Yao, J.C., Hicks, M.E., Abbruzzese, J.L., Tam, A.L., Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J Clin Oncol 31 (2013), 17–22.
8. Sundaresan, T.K., Sequist, L.V., Heymach, J.V., Riely, G.J., Jänne, P.A., Koch, W.H., Sullivan, J.P., Fox, D.B., Maher, R., Muzikansky, A., Webb, A., Tran, H.T., Giri, U., Fleisher, M., Yu, H.A., Wei, W., Johnson, B.E., Barber, T.A., Walsh, J.R., Engelman, J.A., Scott, S.L., Kapur, R., Maheswaran, S., Toner, M., Haber, D.A., Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res 22 (2016), 1103–1110.
9. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N.Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C.R., Nohadani, M., Eklund, A.C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P.A., Swanton, C., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892.
10. Crowley, E., Di Nicolantonio, F., Loupakis, F., Bardelli, A., Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10 (2013), 472–484.
11. Oxnard, G.R., Paweletz, C.P., Kuang, Y., Mach, S.L., O'Connell, A., Messineo, M.M., Luke, J.J., Butaney, M., Kirschmeier, P., Jackman, D.M., Jänne, P.A., Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20 (2014), 1698–1705.
12. Bartels, S., Schipper, E., Kreipe, H.H., Lehmann, U., Comprehensive molecular profiling of archival bone marrow trephines using a commercially available leukemia panel and semiconductor-based targeted resequencing. PLoS One, 10, 2015, e0133930.
13. Pirker, R., Filipits, M., Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. Cancer Metastasis Rev 35 (2016), 141–150.
14. Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F.O., Hesch, R.D., Knippers, R., DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001), 1659–1665.
15. Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A., Anker, P., About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313 (2001), 139–142.
16. Bronkhorst, A.J., Wentzel, J.F., Aucamp, J., van Dyk, E., du Plessis, L., Pretorius, P.J., Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta 1863 (2016), 157–165.
17. Sozzi, G., Conte, D., Leon, M., Ciricione, R., Roz, L., Ratcliffe, C., Roz, E., Cirenei, N., Bellomi, M., Pelosi, G., Pierotti, M.A., Pastorino, U., Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21 (2003), 3902–3908.
18. Cai, X., Janku, F., Zhan, Q., Fan, J.B., Accessing genetic information with liquid biopsies. Trends Genet 31 (2015), 564–575.
19. Bartels, S., Schipper, E., Hasemeier, B., Kreipe, H., Lehmann, U., Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. Oncotarget 7 (2016), 30084–30093.
20. Borsu, L., Intrieri, J., Thampi, L., Yu, H., Riely, G., Nafa, K., Chandramohan, R., Ladanyi, M., Arcila, M.E., Clinical application of picodroplet digital PCR technology for rapid detection of EGFR T790M in next-generation sequencing libraries and DNA from limited tumor samples. J Mol Diagn 18 (2016), 903–911.
21. Mogi, A., Kuwano, H., TP53 mutation in nonsmall cell lung cancer. J Biomed Biotechnol, 2011, 2011, 583929.
22. Deben, C., Deschoolmeester, V., Lardon, F., Rolfo, C., Pauwels, P., TP53 and MDM2 genetic alterations in non-small cell lung cancer: evaluating their prognostic and predictive value. Crit Rev Oncol Hematol 99 (2016), 63–73.
23. Gu, J., Zhou, Y., Huang, L., Ou, W., Wu, J., Li, S., Xu, J., Feng, J., Liu, B., TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: evidence from a meta-analysis. Mol Clin Oncol 5 (2016), 705–713.
24. Deben, C., Van den Bossche, J., Van Der Steen, N., Lardon, F., Wouters, A., de Beeck, K.O., Hermans, C., Jacobs, J., Peeters, M., Van Camp, G., Rolfo, C., Deschoolmeester, V., Pauwels, P., Deep sequencing of the TP53 gene reveals a potential risk allele for non–small cell lung cancer and supports the negative prognostic value of TP53 variants. Tumour Biol, 39, 2017 1010428317694327.
25. Luo, J., Shen, L., Zheng, D., Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep, 4, 2014, 6269.
26. Wan, J.C., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J.D., Caldas, C., Pacey, S., Baird, R., Rosenfeld, N., Liquid biopsies come of age: towards implementation of circulating tumor DNA. Nat Rev Cancer 4 (2017), 223–238.